PGEN News and Press, Precigen Inc. From 02/06/24

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene...

2024-01-19 19:39:39 ET Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients wi...

2024-01-16 09:33:30 ET More on Precigen Precigen: Big Ambitions But Outstanding Funding Concerns Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Financial information for Precigen For further details see: Prec...

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission PR Newswire – Designation is an important step toward bringing this potentially life-changing therapy to European patients ...

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire – PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated ...

2023-12-29 17:32:32 ET More on Precigen Precigen: Big Ambitions But Outstanding Funding Concerns Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Financial information for Precigen For further details see: Prec...

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md. , Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therap...

2023-12-18 08:08:27 ET Summary Precigen is a biopharmaceutical company with ambitions to develop cell therapy and gene engineering platforms for various markets. They are currently focusing on CAR-T cell therapy, AdenoVerse Immunotherapy, ActoBiotics, and Multifunctional Therapeut...

Precigen to Participate in the JMP Securities Hematology and Oncology Summit PR Newswire GERMANTOWN, Md. , Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell the...

2023-11-22 14:22:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through...